Name:SLAM family member 7 Target Synonym:Novel Ly9;CS1;CD_antigen=CD319;Membrane protein FOAP-12;CRACC;SLAMF7;Protein 19A;SLAM family member 7;CD2 subset 1;CD2-like receptor-activating cytotoxic cells
Number of Launched Drugs:1 Number of Drugs in Clinical Trials:3 Lastest Research Phase:Approved
Immobilized Human SLAMF7, Fc Tag (Cat. No. SL7-H5256) at 2 μg/mL (100 μL/well) can bind Humanized Anti-Human CS1 MAb with a linear range of 0.3-5 ng/mL (Routinely tested).
Immobilized Humanized Anti-Human CS1 MAb at 1 μg/mL (100 μL/well) can bind Biotinylated Human SLAMF7, Avitag,His Tag (Cat. No. SL7-H82E0) with a linear range of 0.6-5 ng/mL (Routinely tested).
SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.
A-Z